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Abstract: Nonalcoholic fatty liver disease (NAFLD), tightly linked to the metabolic syndrome (MS),
has emerged as a leading cause of chronic liver disease worldwide. Since it is potentially progressive
towards non-alcoholic steatohepatitis (NASH) and hepatic fibrosis, up to cirrhosis and its associated
complications, the need for predictive factors of NAFLD and of its advanced forms is mandatory.
Despite the current “gold standard” for the assessment of liver damage in NAFLD being liver biopsy,
in recent years, several non-invasive tools have been designed as alternatives to histology, of which
fibroscan seems the most promising. Among the different serum markers considered, serum uric
acid (SUA) and ferritin have emerged as possible predictors of severity of liver damage in NAFLD.
In fact, as widely described in this review, they share common pathogenetic pathways and are both
associated with hepatic steatosis and MS, thus suggesting a likely synergistic action. Nevertheless,
the power of these serum markers seems to be too low if considered alone, suggesting that they
should be included in a wider perspective together with other metabolic and biochemical parameters
in order to predict liver damage.
Keywords: SUA; liver damage; fibrosis; NASH; serum markers; oxidative stress; insulin resistance;
metabolic syndrome
1. Introduction
Nonalcoholic fatty liver disease (NAFLD), tightly linked to metabolic syndrome (MS), has emerged
as a leading cause of chronic liver disease worldwide with a rapidly growing prevalence in the general
population, ranging between 20% and 30%, and paralleling the epidemics of obesity and type 2 diabetes
mellitus (T2DM) all over the world [1,2]. NAFLD encompasses a clinical-pathologic spectrum of liver
diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the more aggressive
form of NAFLD, which can progress to cirrhosis and its associated complications [3,4].
Unfortunately, the only validated method to diagnose NASH, the potentially evolving form of
NAFLD, is liver biopsy. Nonetheless, this procedure is limited by intra and inter-observer variability,
sampling errors and invasiveness, thus letting impossible its feasibility in such a large number of
patients with NAFLD. Several scores have been designed in the attempt to diagnose NASH and fibrosis
stage without histological data, but the debate on their real utility is still ongoing [5]. Fibroscan is
emerging as a reliable tool to identify fibrosis in a non-invasive way, but still the large “grey area” of
its results does not allow one to discriminate the entity of fibrosis in a large portion of patients with
NAFLD [6].
During the last few years, among the several parameters evaluated as possible predictors of
NAFLD, serum uric acid (SUA) and ferritin have emerged. In fact, increasing evidence has shown
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that SUA levels as well as high ferritin are associated with the metabolic insulin resistance syndrome,
higher body fat content and more severe liver damage.
2. Uric Acid
Serum uric acid (SUA) is a product of purine metabolism in humans and originates from
hypoxanthine after a double enzyme catalysis by xanthine oxidase (XO) in the liver. Its production is
regulated by the endogenous (nucleoproteins originating from cellular metabolism) and exogenous
(dietary) precursor proteins delivered to the liver, whereas its excretion is controlled by the kidneys
through renal plasma flow, glomerular filtration and proximal tubular exchange. Therefore, an
impairment in this balance, caused by either an over generation of uric acid, like in MS and diets rich
in fructose and purines or by a reduction in its excretion, as in acute renal failure or consequent to
some drugs (ciclosporin, ethambutol, pyrazinamide, and cytotoxic chemotherapy), can lead to high
SUA levels [7,8].
3. Serum Uric Acid and Metabolic Syndrome Clinical Manifestations
SUA is the most common and well-studied risk factor for developing gout. In addition, beyond
contributing to the pathogenesis of gout, arthritis, and chronic nephropathy, hyperuricemia is
associated with the so-called “cardio-metabolic diseases” including cardiovascular disease and all the
metabolic diseases associated with MS [9]. Several studies reported a significantly higher prevalence
of MS (up to 60%) and its components such as hypertension, hyperinsulinemia, hypertriglyceridemia
and diabetes in the hyperuricemic population, suggesting that hyperuricemia might be an indicator
for early diagnosis of MS and of its different clinical manifestations [10–12]. Moreover, a meta-analysis
of prospective cohort studies provided strong evidence that a high level of SUA is a risk factor for
developing T2DM in middle-aged and older people, independently of other established metabolic risk
features [13].
4. Serum Uric Acid and Nonalcoholic Fatty Liver Disease (NAFLD)
Lonardo et al. [14] firstly described an association between NAFLD and serum uric acid levels in
a small case-control study of Italian patients with ultrasound-diagnosed NAFLD.
The relationship between SUA and NAFLD was then confirmed in cross-sectional and prospective
studies in which SUA resulted to be an independent risk factor for NAFLD [15,16]. More recently in
two different meta-analyses of prospective studies including very large numbers of participants, it was
shown a significant higher risk of NAFLD in subjects with higher SUA compared to those with lower
levels. A linear dose-response effect between SUA and NAFLD was reported with each 1 mg increase
of SUA leading to 21% rise in NAFLD risk [17,18]. Moreover, in patients with established coronary
artery disease, hyperuricemia was reported to be a potent predictor of mortality in overweight or
obese patients in whom liver steatosis was highly prevalent [19].
The mutual relationship between NAFLD and SUA was shown in another study aimed at
exploring the causal relationship and underlying mechanisms linking NAFLD and hyperuricemia.
By analyzing prospectively a cohort of 5541 patients, NAFLD resulted strongly associated with the
risk of developing hyperuricemia over a period of seven years. In a second part of the same study,
xantine oxidase was demonstrated to be the mediator of this relationship through the activation of the
ucleotide-binding oligomerization domain-like (NOD-like) receptor family pyrin domain containing 3
(NLRP3) inflammasome [20] in both in HepG2 cells and mice, as explained in the next pharagraph.
However, a major limitation of these study designs is their inability to show the biological mechanisms
underpinning the association between SUA and NAFLD. Furthermore, experimental animal models
supporting this association do not always mirror human biology.
Interestingly, Sirota et al. [21] examined the association between SUA levels and NAFLD in
a large population-based study from the United States including 10,732 non-diabetic adults who
participated in the National Health and Nutrition Examination Survey 1988–1994. The Authors found
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that the odds ratio for NAFLD was significantly higher in patients with the highest SUA values (3rd
and 4th quartiles) compared to subjects in the lowest quartiles. In addition, after adjusting for the
known risk factors, uric acid (4th quartile) remained significantly associated with NAFLD. Thus, they
concluded that elevated SUA level is independently associated with ultrasound-diagnosed NAFLD
and with increasing severity of NAFLD as evaluated by ultrasonography. These data were in line with
previous results by Petta et al. [22] obtained in a group of patients with histologically proven NAFLD.
They had demonstrated that hyperuricemia was associated with histological features of liver disease,
representing an independent risk factor for higher grade of steatosis, lobular inflammation and higher
NAFLD Activity Score (NAS), the histological score routinely used for the diagnosis and grading of
NASH. Thus, these data confirm and extend the results obtained in Asiatic subjects also to Caucasian
patients, consolidating the relationship between NAFLD and SUA.
Finally, Afzali et al. [23], on the basis of the observation that elevated SUA levels strongly reflect
and may even cause oxidative stress, insulin resistance (IR), and MS, and that experimental, and in
in vitro models indicate that uric acid is able to induce inflammatory responses, all known risk factors
involved in the pathogenesis and in the progression of liver disease of different etiology, addressed
the question whether the baseline SUA level was associated with the incidence of hospitalization
or death due to cirrhosis. These authors analyzed 5518 participants from the first National Health
and Nutrition Examination Survey during a mean follow-up of 12.9 years (range 5.4–21 years) and
demonstrated that subjects with the higher uric acid values had a higher risk of cirrhosis related
hospitalization or death even after adjustment for important causes and risk factors of chronic liver
disease. In addition, patients with higher SUA levels had a greater probability of elevated serum ALT
and GGT. They suggested that the negative effect of SUA was mediated by the induction by uric acid
of endothelial dysfunction, IR, oxidative stress and systemic inflammation, which are known risk
factors for the development and progression of liver disease of different etiology. However, despite
this fascinating hypothesis, a major limitation of these results obtained in clinical studies is that the
direct demonstration in patients with NAFLD of the mechanisms underpinning the negative effect of
SUA is still missing.
5. Relationship between Uric Acid and NAFLD/Metabolic Syndrome: Possible Mechanisms
Accumulating clinical evidence suggests that hyperuricemia is strongly associated with
MS/NAFLD, and abnormal glucose metabolism and IR, as well as oxidative stress and NLRP3
inflammasome involvement, have been pointed out as possible linking conditions [11,24]. The possible
interactions of the different mechanisms involved are schematically depicted in Figure 1.
Int. J. Mol. Sci. 2016, 17, 548 3 of 14 
values (3rd and 4th quartiles) compared to subjects in the lowest quartiles. In addition, after 
adjusting for the known risk factors, uric acid (4th quartile) remaine  significantly associated with 
NAFLD. Thus, they concluded that elevated SUA level is independently associated with 
ultrasound-diagnosed NAFLD and with increasing severity of NAFLD as evaluated by 
ultrasonography. These data were in line with previous results by Petta et al. [22] obtained in a 
group of patients with histologically proven NAFLD. They had demonstrated that hyperuricemia 
was associated with histological features of liver disease, representing an independent risk factor for 
higher grade of steatosis, lobular inflammation and higher NAFLD Activity Score (NAS), the 
histological score routinely used for the diagnosis and grading of NASH. Thus, these data confirm 
and extend the results obtained in Asiatic subjects also to Caucasian patients, consolidating the 
relationship between NAFLD and SUA. 
Finally, fzali et al. [23], on the basis of the observation that elevated SUA levels strongly 
reflect and may even cause oxidative stress, insulin resistance (IR), and MS, and that experimental, 
and in in vitro models indicate that uric acid is able to induce inflammatory responses, all known 
risk factors involved in the pathogenesis and in the progression of liver disease of different etiology, 
addressed the question whether the baseline SUA level was associated with the incidence of 
hospitalization or death due to cirrhosis. These authors analyzed 5518 participants from the first 
National Health and Nutrition Examination Survey during a mean follow-up of 12.9 years (range 
5.4–21 years) and demonstrated that subjects with the higher uric acid values had a higher risk of 
cirrhosis related hospitalization or death even after adjustment for important causes and risk factors 
of chronic liver disease. In addition, patients with higher SUA levels had a greater probability of 
elevated serum ALT and GGT. They suggested that the negative effect of SUA was mediated by the 
induction by uric acid of endothelial dysfunction, IR, oxidative stress and systemic inflammation, 
which are known risk factors for the development and progression of liver disease of different 
etiology. However, despite this fascinating hypothesis, a major limitation of these results obtained 
in clinical studies is that the direct demonstration in patients with NAFLD of the mechanisms 
underpinning the negative effect of SUA is still missing. 
5. Relationship betwe n Uric Acid and NAFLD/Metabolic Syndrome: Pos ible Mechanisms 
ccu ulating clinical evidence suggests that eruricemia is ly iated it  
S/NAFLD, and abnormal glucose metabolism and IR, as wel  as oxidative stress a  3 
i fl  involvement, have been pointed out as possible linking conditions [11,24]. The 
possible i teractions of the different mechanisms involved are schematically depicted in Figure 1. 
 
Figure 1. Pathogenetic pathways of the association between serum uric acid and NAFLD. 
Abbreviations: SUA, serum uric acid; ROS, reactive oxygen species; ER, endoplasmic reticulum; 
NAFLD, non-alcoholic fatty liver disease. 
Furthermore, a very recent study by a Chinese group, has focused on the progression of 
NAFLD in hyperuricemic subjects, showing a key role of perturbations of phospholipases, purine 
nucleotide degradation and Liver X receptor/retinoid X receptor. In particular, they demonstrated 
an increase in oxidative stress and IR driven by an upregulation of phospatidic acid and cholesterol 
ester metabolism and a downregulation of the acid uric precursor, namely inosin [25]. 
Fig re 1. Pathogenetic pathways of the association between serum uric acid and NAFLD.
reviations: SUA, serum uric acid; ROS, reactive oxygen species; ER, endoplas ic reticulu ;
F , -alc lic f tt li r i .
Furthermore, a very recent study by a Chinese group, has focused on the progression of NAFLD
in hyperuricemic subjects, showing a key role of perturbations of phospholipases, purine nucleotide
degradation and Liver X receptor/retinoid X receptor. In particular, they demonstrated an increase in
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oxidative stress and IR driven by an upregulation of phospatidic acid and cholesterol ester metabolism
and a downregulation of the acid uric precursor, namely inosin [25].
5.1. Interaction between Uric Acid and Insulin
Insulin acts on the proximal renal tubule fostering acid uric reabsorption and increasing renal
cellular metabolism, thus leading to hyperuricemia. Indeed, elevated SUA levels may prompt the
development of IR by reducing endothelial nitric oxide (NO) bioavailability and supply to cells [26].
In addition, in an experimental model, mice fed with hyperuricemia-inducing diet (HUA)
presented significantly lower insulin sensitivity and impaired glucose metabolism compared to
those with a standard diet, as well as higher levels of both serum and intrahepatic triglycerides.
In particular, hyperuricemia inhibited a protein kinase B (AKT) response to insulin by decreasing its
phosphorylation and conversely increasing the phosphorylation of the insulin receptor substrate-1
(IRS1) in liver, muscle and fat tissue, thus fostering the onset of IR. This effect seems to be secondary to
uric acid induced radical oxygen species (ROS) and activation of the NLRP3 inflammasome [27,28].
These data were confirmed also in HepG2 cell cultures exposed to different concentrations of uric
acid. Not surprisingly, administration of probenecid, a uric acid transport inhibitor into cells, or
the antioxidant N-acetylcisteine, diminished intracellular triglycerides accumulation and improved
insulin-signaling.
5.2. Uric Acid and Lipid Metabolism
Beyond hyperinsulinemia, uric acid is responsible of mitochondrial oxidative stress [29], sterol
regulatory element-binding protein 1 (SREBP-1) activation induced by endoplasmic reticulum
(ER) stress [30] and NLRP3 inflammasome involvement [31], all causative factors of lipid
metabolism impairment.
Moreover, evidence suggests that uric acid could originate from fructose metabolism, which is well
known for inducing hepatic steatosis being directly metabolized to triglycerides in the liver [32], and
be responsible for mitochondrial oxidative stress. In turn, SUA amplifies the lipogenic effect of fructose
by upregulating its metabolic enzymatic reactions [33]. In cultured HepG2 cellular lines exposed to
fructose, increased intracellular levels of uric acid and triglycerides were registered. Interestingly,
allopurinol effectively prevented the formation of uric acid after exposure to fructose [29].
5.3. Mitochondrial and Endoplasmic Reticulum (ER) Oxidative Stress
Oxidative stress plays a key-role in steatosis induced by uric acid. In the study by
Lanaspa et al. [29], cellular exposure to high SUA levels determined mitochondrial oxidative stress with
generation of ROS by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. As a result,
the activity of aconitase, an enzyme involved in the acid citric circle, was markedly reduced leading
to accumulation of citrate, a substrate for hepatic de novo lipogenesis and subsequent intracellular
fat generation.
Furthermore, ROS production promotes ER stress, which is determinant of fat accumulation
in steatosis. In fact, alterations in its homeostasis have been demonstrated in human HepG2 cells
and mice models of fatty liver [34,35]. ER is a site of protein folding and production of lipids and
sterols. If a perturbation in this compartment occurs, misfolded and unfolded proteins accumulate
and activate the unfolded protein response (UPR) signaling pathways, which regulate hepatic lipid
metabolism and promote fat accumulation in the liver because of the expression of genes encoding for
lipogenic enzymes driven by the transcriptional factor SREBP-1c. Uric acid has been shown to induce
the expression of unfolded response protein (URP)-inducible and to increase the cleavage of SREBP-1c
into the mature form and its nuclear translocation, thus enhancing the de novo lipogenesis. This data
has been shown in both HepG2 cells and primary mice hepatocytes [30].
Despite these data, acute elevations seem to provide antioxidant protection, and uric acid
contributes >50% of the antioxidant capacity of our organism. In fact, it has a direct effect on
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the inhibition of free radicals, protecting the cell membrane and DNA. The antioxidant activity
of SUA also occurs in the brain, being a protector for several disease such as multiple sclerosis and
neurodegenerative disease, as well as cardiac and renal toxicity [36]. Thus, an eventually beneficial
action could be speculated also on the liver.
In addition, there is still no consensus if uric acid is a protective or a risk factor; however, it seems
that the quantity and the duration of the concentration of the uric acid in the blood is essential for
this answer, possibly being the acute increase in its protective levels whereas chronic elevated levels
are dangerous.
5.4. The Ucleotide-Binding Oligomerization Domain-Like (NOD-Like) Receptor Family Pyrin Domain
Containing 3 (NLRP3) Inflammasome
Another factor which has been reported to be strongly involved in the pathogenesis of uric acid
toxicity is NLRP3 inflammasome, an intracellular multiprotein complex that is assembled and activated
by pathogen-associated and damage-associated molecular patterns with subsequent production of
pro-inflammatory and pro-fibrotic cytokines (IL-1β and IL-18). It plays a central role in obesity and
IR and has been involved in dyslipidemia and lipid accumulation in hepatocytes [28,31]. The NLRP3
inflammasome is activated by uric acid, both directly and indirectly through ROS production [37] and
recent evidence has demonstrated that it contributes to hepatic steatosis and insulin resistance in a
murine model [28]. This suggestion was confirmed in cultured HepG2 and L02 cellular lines, where
the NLRP3 inflammasome knock-down cells decreased the uric acid-induced hepatic free fatty acids
(FFAs) accumulation [31].
In conclusion, SUA is able to regulate lipid production and to foster the onset of metabolic
disorders and NAFLD through multifaceted pathways. Thereby, evidence is accumulating on the
benefit of lowering SUA levels in NAFLD by using drugs commonly employed in the treatment of
hyperuricemia, like allopurinol or probenecid.
6. Ferritin
Hyperferritinemia is a frequent finding in the general population, is detected in 30%–40% of the
patients with MS/NAFLD, and has been suggested as a marker of severity of the disease.
The difficulty in the interpretation of increased ferritin is related to the multiple causes that can
lead to its increase, initially identified as marker of iron overload, following the increase of transferrin
saturation, and also in the presence of severe hepatic necrosis. Furthermore, other more frequent
causes need to be considered, namely the presence of inflammation, since ferritin behaves as a protein
of acute phase and it can also be induced in the setting of systemic inflammation, like in rheumatologi,
infectious or neoplastic diseases, and alcohol abuse, where ferritin levels rapidly decrease with alcohol
abstinence. However, enlarging the most common cause of hyperferritinemia identified in the last
years is the presence of the MS, to which NAFLD is frequently associated.
7. Ferritin and Metabolic Syndrome Clinical Manifestations
Hyperferritinemia is detected in about one-third of patients with NAFLD and the MS and its
levels seem to be directly correlated with the severity of IR [38,39].
The first reports on the relationship between ferritin, IR/T2DM and the MS study in Europe
were published in the 1990s. In 1998, Ford et al. [40] reported the results of a case-control study in
Europe, demonstrating that subjects with hyperferritinemia had a 2.4-fold higher risk of developing
T2DM. In addition, Salonen [41] showed in a prospective study that increased ferritin levels precede
the development of diabetes and Kim obtained the same results in a very large cohort of Korean
subjects [42]. In addition, cross-sectional studies found that elevated ferritin levels were associated with
central obesity [43], hypertension [44], and dyslipidemia [45], all manifestations of the MS. Moreover,
Iwasaki highlighted an association between serum ferritin, visceral fat and subcutaneous adiposity
and suggested that serum ferritin concentration may be a useful indicator of systemic fat content and
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degree of IR [46]. In addition, Alam et al. [47] demonstrated that obesity led to hyperferritinemia
irrespective of actual body iron story, advocating a state of subclinical inflammation responsible for
high levels of ferritin.
Others demonstrated in population-based studies that moderate to markedly increased ferritin
concentrations represent a biological biomarker predictive of early death in a dose-dependent
manner [48]. Thus, even if in this study, information on the presence of liver steatosis was lacking, it is
very likely that ferritin may be a predictor of early death also in the setting of NAFLD.
8. Ferritin and NAFLD
The tight link between ferritin and insulin dysregulation was shown by Fernandez-Real [49], who
proposed ferritin as a marker of IR. Zelber-Sagi et al. [50]demonstrated that among different metabolic
features, insulin was the strongest predictor of increased serum ferritin levels and that the association
between serum ferritin and MS was mediated by NAFLD.
A French group coined the term of “dysmetabolic iron overload syndrome” (DIOS), to indicate subjects
with increased ferritin levels, with normal or only mildly increased transferrin saturation, in the
presence of liver steatosis, IR and two or more components of the MS, along with moderate hepatic iron
accumulation with the typical pattern of mixed parenchymal and mesenchymal iron deposition [51].
However, it was also observed that several patients with NAFLD, IR and manifestations of MS may
have increased ferritin even in the absence of increased iron stores.
In addition, Kim et al. [42] reported that serum ferritin levels predict incident non-alcoholic fatty
liver disease in healthy Korean men.
9. Relationship between Ferritin and NAFLD/Metabolic Syndrome: Possible Mechanisms
Numerous data demonstrate that hepatic iron accumulation could elicit the onset of metabolic
imbalance and liver damage and figure out the DIOS or more recently called “insulin-resistance
associated with iron overload syndrome”.
The liver has a central role in iron metabolism as it is the principle source of hepcidin, the
regulatory peptide hormone of iron homeostasis. In fact, in response to several stimuli, like excessive
iron deposits, inflammatory signals (IL-6) or ER-stress, hepcidin is overexpressed and determines
a reduction in iron intestinal absorption and an increase in iron retention from macrophage and
hepatocytes [52,53]. In addition, hepatocyte necrosis, with subsequent erythrophagocytosis by
macrophages, and the systemic inflammatory state induced by obesity and NAFLD itself, may
predispose individuals to increased hepcidin levels.
Many mechanisms linking iron and liver damage have been described. Firstly, iron, once
accumulated in the liver, causes oxidative stress through the Fenton and Haber–Weiss chemistry
with production of ROS and damage to membranes, proteins and DNA. Secondly, ferritin itself, which
is the expression of iron storage in the liver, behaves as a real pro-inflammatory cytokine directly
activating the hepatic stellate cells via Nuclear Factor κB (NFκB) cascade and inducing fibrogenesis [54].
Nevertheless, the role of hepatic iron and progression of liver disease is still to be fully elucidated.
In addition, very recent data suggest a possible role of splenic iron accumulation in promoting
liver damage. However, these results need further confirmations [55].
9.1. Pathogenesis of DIOS (Dysmetabolic Iron Overload Syndrome)
Several explanations for the correlation between high ferritin levels and NAFLD have been
proposed, namely IR, erythrophagocytosis by hepatic macrophages and dysregulation of proteins
and pathways involved in iron homeostasis. Among the latter, hepcidin seems to have a key role in
iron accumulation in NAFLD [56,57], as increased levels of this peptide have been detected in these
patients [58,59], as well in the paediatric NAFLD population [60]. Furthermore, an influence of genetic
factors has been considered, in particular the heterozygosis state of β-thalassemia and mutations in
the HFE gene responsible for hereditary hemochromatosis (HH) [38,61,62] (Figure 2).
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9.2. Hyperferritinemia and Insulin-Resistance
The relationship between hyperferritinemia and IR seems to be mutual. In fact, early in vitro
studies have suggested that insulin might determine a rapid and marked stimulation of iron uptake
by fat cells, by a redistribution of transferrin receptors from an intracellular membrane compartment
to the cell surface [49]. On the other hand, systemic iron overload may prompt the onset of diabetes
mellitus (DM) consequent to an impairment in pancreatic β-cells function due to intra-parenchymal
iron deposition. In fact, because of oxidative stress, β-cells are less sensitive to glucose stimulation and
die by to apoptosis with consequent reduction in insulin production [63].
The effect of iron overload on glucose metabolism has been investigated in animal models. In
a study by Choi et al. [64], mice fed with a standard diet enriched in iron, presented higher levels
of ferritin, hepcidin and inflammatory cytokines, as well as a higher degree of IR and metabolic
dysregulations, mainly driven by an overexpression of genes involved in either gluconeogenesis
or lipogenesis. These features were exasperated in mice fed with high fat diet (HFD) enriched
with iron, suggesting a synergistic effect of fat and iron. The authors have speculated that insulin
stimulates ferritin synthesis via inflammatory pathways and enhances hepcidin expression. On the
other hand, iron interferes with insulin inhibition of glucose production by the liver and decreases
the hepatic extraction and metabolism of insulin, leading to peripheral hyperinsulinemia. These data
were confirmed by Dongiovanni et al. [65], who showed that an iron-enriched diet in mice led to
the development of IR, probably due to the secretion of adipokines by the visceral adipose tissue
consequent to iron accumulation.
Recent data by Vecchi et al. [66] further explored the relationship between glucose and iron
metabolism and showed a new regulatory pathway in iron homeostasis driven by gluconeogenic
stimuli and with the major actors being hepcdin and PPARGC1A, a transcriptional coactivator of genes
involved in gluconeogenesis. Therefore, in conditions like NAFLD, obesity and T2DM, persistently
activated gluceoneogenesis may result in overstimulation of hepcidin and iron accumulation.
The interplay between iron and insulin has been also confirmed by experimental data that showed
how iron depletion could elicit an over expression and higher affinity of insulin receptors, as well as an
increase in the expression of molecules involved in the intracellular signal cascade activated by insulin
receptors and of genes involved in glucose uptake [57].
9.3. Hyperferritinemia and Adipose Tissue
The adipose tissue behaves as an endocrine organ, which under a condition of chronic
inflammation, as in NAFLD, releases adipokines in the bloodstream, thus altering glucose and iron
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homeostasis and may determine a condition of subclinical inflammation itself [47,67]. Many adipokines
play a central role in this scenario, namely adiponectin, leptin and resistin [57]. Adiponectin, which is
an anti-steatotic and anti-inflammatory adipokine, is reduced in dysmetabolic conditions like NAFLD,
IR and T2DM, and seems to predict the severity of liver inflammation and fibrosis. In fact, it has the
capability of inducing the transcription of key genes in iron metabolism, like the hemeoxygenase-1
(HO-1), determining lower iron levels in hepatocytes, thus preventing apoptosis. Conversely, leptin,
an adipokine involved in the control of food intake and energy consumption, seems to upregulate
hepcidin synthesis, thus contributing to DIOS pathogenesis.
Finally, resistin is able to either impair glucose tolerance or reduce glucose uptake from muscular
tissue or induce an inhibitor of insulin signaling namely SOCS3 (Suppressor of cytokine signaling 3),
thus eliciting a condition of IR.
In line with this are the results by Beckry et al. [68] who have shown the ectopic expression of
hepcidin in white adipose tissue of obese individuals and that of leptin, usually increased in obese
subjects, was able to enhance hepcidin mRNA in vitro. In addition, Green et al. [69] have demonstrated
how isolated primary rat adipocytes exposed to iron become insulin-resistant decreasing insulin
mediated glucose transport and fostering lipolisis. On the other hand, a “portal vein theory” has been
proposed and comprises the concept that visceral adipose tissue and/or the gut release into the portal
vein increasing amounts of FFAs and pro-inflammatory factors, which, in turn, reach the liver and
contribute to the onset of hepatic IR and steatosis. However, further studies are needed for a better
comprehension of this casual link [70].
10. Hyperferritinemia and Severity of Liver Damage in NAFLD
Iron and ferritin have been hypothesized to foster the progression of organ damage, including
hepatic and cardiovascular diseases.
In 2001, our group showed that hyperferritinemia with normal transferrin saturation was a
hallmark of a glucose/lipid metabolism disorder and, when associated with multiple metabolic
abnormalities and iron overload, identified patients at risk for NASH. Interestingly, we observed
that patients in whom ferritin remained elevated despite lifestyle modifications (diet, weight loss,
physical activity) differed from those whose ferritin normalized, presenting the former a more severe
liver disease. We hypothesized that the increase of ferritin possibly reflected a synergistic induction
of its synthesis because of increased iron stores, hepatic steatosis and subclinical inflammation. In
contrast, when the increase in serum ferritin was a consequence only of altered lipid metabolism, it
was reversible with diet and unrelated to iron stores [71].
Since then, several other studies analyzed the relationship between ferritin, iron overload and
severity of liver damage in patients with NAFLD. Bugianesi et al. [38] demonstrated that increased
ferritin levels are markers of severe histologic damage, but not of iron overload and that iron burden
and HFE mutations do not contribute significantly to hepatic fibrosis in the majority of patients with
NAFLD. Manousou et al. [72] evaluated in 111 NAFLD patients the relationship between serum ferritin
and features of MS with respect to histological inflammation and/or fibrosis. Interestingly, ferritin
resulted a good predictor of advanced liver disease, with respect to both NASH and fibrosis. In
addition, Kowdley et al. [73] demonstrated that elevated serum ferritin is an independent predictor of
histologic severity and advanced fibrosis among patients with NAFLD. He found in a cohort of 628
biopsy-proven NAFLD with hyperferritinemia that ferritin, besides being significantly associated with
markers of liver damage (elevated serum ALT, AST and decreased platelets) and of iron overload (iron,
transferrin-iron saturation and iron stain grade), was associated with more severe histologic features
of NAFLD, including steatosis, hepatocellular ballooning, increased NAFLD Activity Score (NAS) and
diagnosis of NASH. In addition, ferritin was also independently associated with advanced hepatic
fibrosis and with higher NAS, the latter even among patients without hepatic iron deposition. The
authors concluded that serum ferritin was useful to identify NAFLD patients at risk for NASH and
advanced fibrosis.
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These data were confirmed in a cohort of 108 Korean biopsy proven NAFLD patients in whom a
positive correlation between ferritin level, metabolic alterations, liver fibrosis and NASH was found.
Nevertheless, the association between ferritin and histology resulted weaker compared to another
serum marker resulting from hepatocytes apoptosis, namely fragmented cytokeratin-18 (CK-18) [74].
Conversely, Angulo et al. [75] retrospectively analyzed in 1404 NAFLD patients the accuracy
of serum ferritin in determining the presence and severity of liver fibrosis, and whether combining
non-invasive fibrosis scoring systems with serum ferritin analysis could increase the accuracy of those
tests. Although serum levels of ferritin correlated with more-severe liver fibrosis; however, either
the performance of ferritin resulted unsatisfactorily for any grade of fibrosis or the accuracy of the
non-invasive scores did not change with inclusion of serum ferritin. On the basis of adjusted multiple
logistic regression analysis, they concluded that serum ferritin levels alone had a low level of diagnostic
accuracy for the presence or severity of liver fibrosis in patients with NAFLD.
Similar results were reported by Yoneda et al. [76], who analyzed 1201 biopsy-proven NAFLD
patients previously enrolled into the Japan Study Group of NAFLD and belonging to a large Japanese
cohort database of NAFLD patients. By comparing serum ferritin levels and hepatic histology,
the authors showed that ferritin increased with increasing histological grade of steatosis, lobular
inflammation and ballooning and that at multivariate analyses it was independently associated with
steatosis grade and fibrotic stage. However, ferritin showed a suboptimal performance as predictive
test of any degree of liver fibrosis, possibly because several other factors including sex and metabolic
features could have interfered. The conclusion of the study was that serum ferritin had a low diagnostic
accuracy for detecting fibrosis in NAFLD patients when considered alone.
Nevertheless, ferritin has also been included in serum panels in order to detect liver damage
non-invasively. One of these is the NAFIC score, which relies on ferritin, insulin and type IV collagen
serum levels and which has been tested in a cohort of 147 biopsy-proven NAFLD and validated in
another cohort of 355 patients from nine hepatologic centers in Japan. A cut-off of two has been
identified to diagnose the presence of NASH in NAFLD patients, with a sensitivity and a specificity of
63% and 83%, respectively. Later, a new modified NAFIC score was created including higher insulin
values that presented a better diagnostic performance (sensitivity 74%, specificity 75% and Area under
Receiving Operating Characteristic—AUROC 0.801) [77].
Another score which includes ferritin as a variable is the FibroMeter NAFLD score. It consists of
a panel of serum markers and has been shown to have a high diagnostic accuracy for staging liver
fibrosis. In particular, in a study of 235 NAFLD patients, it showed an AUROC of 0.94 for significant
fibrosis (ěF2), 0.93 for severe fibrosis (F3), and 0.9 for cirrhosis [5,78].
In conclusion, increasing data aimed at pointing ferritin as possible predictive factor of liver
damage are accumulating. Despite conflicting and still not conclusive results, it could be speculated
that ferritin might be used as a surrogate marker, especially if combined with other metabolic and
biochemical variables, to identify a more severe liver disease, even if with an intermediate sensitivity
and specificity.
11. Does Hyperferritinemia Reflect Iron Overload?
In an attempt to clarify whether the increase in ferritin observed in patients with NAFLD reflects
iron overload, studies were performed to define a possible association between ferritin and both liver
siderosis and mutations in genes involved in iron metabolism. Interestingly, HFE mutations responsible
for hereditary hemochromatosis resulted non significantly associated either to liver siderosis or
hyperferritinemia and also liver damage did not result as being influenced by the presence of these
mutations [62]. Vice versa, liver damage defined either by more severe fibrosis or presence of NASH,
resulted as significantly associated with the presence of liver siderosis and β thalassemia traits [79].
However, the large majority of studies concluded that the increased ferritin values observed in patients
with NAFLD reflect increased iron stores and acquired and genetic factors predisposing individuals to
lipid and iron metabolism alterations in the presence of subclinical inflammation.
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12. Iron Depletion in Patients with Hyperferritinemia, Metabolic Alterations and NAFLD
Iron is known for causing oxidative stress through the Fenton and Haber–Weiss chemistry with
production of ROS and damage to membranes, proteins and DNA, thus being capable of inducing
liver damage and fibrosis. Ferritin is the primary iron-storage protein and serum ferritin concentration
has historically been used to predict severe fibrosis in chronic liver diseases.
Several studies showed that iron depletion therapy was followed by a reduction in plasma
glucose and by an improvement of insulin sensitivity. Facchini et al. in 2002 [80] demonstrated in
a small series of NAFLD patients, with and without increased ferritin levels, that iron removal in
carbohydrate intolerant patients with clinical evidence of nonalcoholic fatty liver disease was able
to improve insulin sensitivity in the short term (without changes in body weight). Fernandez-Real
showed in a randomized trial that blood letting in high-ferritin T2DM improved insulin sensitivity
and secretion [81]. In addition, Valenti et al. [82] demonstrated that iron depletion by venesection, in
patients with moderate iron overload associated with NAFLD, determined a decrease of both IR and
transaminases, as well as of ferritin levels.
Despite these encouraging data, confirmed also in following studies, the role of iron depletion
in the improvement in liver histology and the natural history of liver disease is still under definition
because of the lack of studies including a large number of patients.
13. Conclusions
NAFLD is recognized as the leading cause of chronic liver disease worldwide, and, in a percentage
of cases, it is potentially progressive towards advanced fibrosis and severe complications. As a
consequence, the need for predictive factors of NAFLD and especially of its progressive forms
is mandatory. In recent years, SUA and ferritin have emerged as possible predictors of hepatic
steatosis and liver damage. Interestingly, some studies have reported high SUA levels in patients with
hyperferritinemia and vice versa, thus suggesting a mutual relationship and a synergistic action [83–85].
In fact, as extensively depicted in this review, SUA and ferritin share common pathogenic
mechanisms, in particular oxidative stress and IR, and are associated with metabolic features, among
the latter obesity and T2DM are the most important. Therefore, it could be speculated that both
SUA and ferritin are the main actors in the multifaceted and complicated scenario of NAFLD and its
dysmetabolic features.
However, given that the majority of studies are based on observational data, well-designed
prospective studies including a large series of patients of different ethnicities are warranted before
a definite role of SUA and ferritin in the pathogenesis of NAFLD can be established. In addition, it
could be of interest to evaluate whether treating hyperuricemia and hyperferritinemia may lead to
NAFLD improvement, and, in turn, whether regression of NAFLD is accompanied by a normalization
of SUA and ferritin levels.
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